INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

INC Research Holdings, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K, filed with the Securities and Exchange Commission on July31, 2017, for the sole purpose of correcting a typographical error. Specifically, the Company has corrected the voting results regarding the stock issuance proposal.

On July31, 2017, the Company held a Special Meeting of Stockholders (the “Meeting”). The certified results of the matters voted upon at the Meeting, which are more fully described in the Company’s definitive proxy statement, filed with the United States Securities and Exchange Commission on June30, 2017 as supplemented on July19, 2017 and July27, 2017, are as follows:

1. Approval of the Agreement and Plan of Merger dated as of May10, 2017 and as it may be amended from time to time, by and between the Company and Double Eagle Parent, Inc. (“inVentiv”), which we refer to as the merger proposal:

This proposal was approved.

2. Approval, for purposes of complying with applicable Nasdaq Listing Rules, of the issuance in excess of 20% of the outstanding shares of the Company’s common stock, to inVentiv’s stockholders and equity award holders to the merger, which we refer to as the stock issuance proposal:

This proposal was approved.

3. Approval, on a non-binding, advisory basis, of the compensation that may be paid or become payable to the named executive officers of the Company in connection with the merger to agreements or arrangements with the Company or its subsidiaries:

This proposal was approved on an advisory (non-binding) basis.

4. Approval to adjourn the Meeting, if necessary or appropriate, to solicit additional proxies if there are insufficient votes at the time of the Meeting to approve the merger proposal or the stock issuance proposal:

This proposal was approved.

About INC RESEARCH HOLDINGS, INC. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.